Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
July 2017

Valbenazine (Ingrezza): The First Drug Approved to Treat TD
Valbenazine (Ingrezza), an inhibitor of vesicular monoamine transporter 2 (VMAT2), is the first medication approved by the FDA to treat tardive dyskinesia.

A Dietary Supplement to Reduce the Risk of Postpartum Depression?
In a small, open-label trial, a dietary supplement decreased the propensity for sadness in postpartum women.

Pimavanserin (Nuplazid) for Parkinson Disease Psychosis
Pimavanserin (Nuplazid), a new molecular entity, is the first drug approved by the FDA to treat Parkinson disease psychosis.

In Brief
Review Finds that Dietary Supplements and Special Diets Do Not Improve Autism Symptoms; Aerobic Exercise Improves Executive Function in Adults with Vascular Cognitive Impairment

Don't Forget Clozapine
A recent survey found that US residents are hesitant to prescribe clozapine (Clozaril and others) for patients with schizophrenia, citing fear of side effects and lack of sufficient training on how to properly prescribe and monitor clozapine treatment.

About the Editorial Advisory Committee

Editorial Advisory Committee:
Ross J. Baldessarini, M.D.
Joseph Biederman, M.D.
Rubin Bressler, M.D.
Andrew W. Brotman, M.D.
Ned Cassem, M.D.
Harold J. DeMonaco, M.S., R.Ph.
Susan R. Donaldson, M.D.
William E. Falk, M.D.
John Greist, M.D.
James W. Jefferson, M.D.
David Katzelnick, M.D.
Samuel J. Keith, M.D.
Martin B. Keller, M.D.
John Racy, M.D.
Eric M. Reiman, M.D.
Jerrold F. Rosenbaum, M.D.
A. John Rush, M.D.
Alan F. Schatzberg, M.D.
Nina R. Schooler, Ph.D.
Michael E. Thase, M.D.
Joanne Doller Wojcik, R.N., M.S.

Editor
Alan J. Gelenberg, M.D.

Assistant Editor
Heather S. Hopkins

Managing Editor
Amy Boynton